第 1 頁 共 2 頁 v 1.1.1 EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 時代天使科技有限公司 | | 股份代號 | 06699 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度末期股息 | | 公告日期 | 2026年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.48 HKD | | 股東批准日期 | 2026年5月19日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.48 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 時代天使科技有限公司 | | 股份代號 | 06699 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度特別股息 | | 公告日期 | 2026年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 其他 | | 特別股息 | | | 股息性質 | 特別股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 4.99 HKD | | 股東批准日期 | 2026年5月19日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 4.99 HKD | | 匯率 | 1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：6699） 截至2025年12月31日止年度的年度業績公告 時代天使科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）欣然公佈本集團截至2025年12月31日止年度（「2025財政年 度」、「報告期間」）的經審核綜合年度業績，連同截至2024年12月31日止年度 「2024財政年度」的比較數字。該等業績亦已經由董事會審核委員會（「審核委員 會」）審閱。 於本公告中，「我們」、「我們的」及「時代天使」指本公司及（除非文義另有規定） 本集團。除文義另有所指外，本公告所用詞彙與日期為2021年6月3日的本公司招 股章程（「招股章程」）所界定者具有相同涵義。 業績概要 2025年是本集團全球持續增長和營運槓桿持續優化的一年。公司在全球市場（中 國內地除外）憑藉卓越的臨床表現贏得客戶，驅動業務實現強勁增長，與此同 時，公司在中國 ...

社会服务 社会服务 2026 年 03 月 22 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -24% -12% 0% 12% 24% 2025-03 2025-07 2025-11 社会服务 沪深300 相关研究报告 《中东局势或利好中国香港地产持续 复苏，多特倍斯 2 月仍保持高增—行 业周报》-2026.3.15 《中国香港房价及租金回暖，市场维 持美国年内两次降息预期—行业周 报》-2026.3.8 《体验与首店经济驱动高端商业体， 三丽鸥上修全年预期—行业周报》 -2026.3.1 | 初敏（分析师） | 李睿娴（分析师） | 程婧雅（分析师） | | --- | --- | --- | | chumin@kysec.cn | liruixian@kysec.cn | chengjingya@kysec.cn | | 证书编号：S0790522080008 | 证书编号：S0790525020004 | 证书编号：S0790525070010 | liruixian@kysec.cn 证书编号：S0790525020004 chengjingya@kysec.cn 证书编号：S07905 ...

S1130525060003 gantanhuan gjzq.com.cn 投资逻辑 受国际石油价格持续上涨及海外能源成本较高的影响，各类化工产品普遍迎来明显涨价，其中溶剂类产品由于其较难 囤货，市场报价持续走高，成为本轮化工品涨价中弹性最显著的品类之一，也直接带动医药中间体、原料药等下游行 业成本抬升。受到上游原材料成本提升影响，下游原料药产品或将迎来提价契机。从供给端看，由于原料药行业在 2020- 2022 年集中扩产，预计供给压力仍然存在，价格有望缓慢传导。从需求端看，下游客户自 23 年 4 月去库存，目前客 户库存水平已长时间处于较低位置。原料药价格已在低位运行较长时间，客户库存水平较低，一旦提价后预计会有较 好持续性，后续可关注价格提升带来的利润弹性。 药品：3 月 20 日，诺华宣布以 20 亿美元预付款及最高 10 亿美元里程碑付款，收购 Synnovation Therapeutics 旗下 泛突变选择性 PI3Kα抑制剂 SNV4818 及相关项目组合，强化 PI3Kα靶点差异化布局，聚焦突变选择性抑制剂在 HR+/HER2-乳腺癌领域的联用潜力，国内建议关注和黄医药 PI3K-ATTC ...

Summary of the Conference Call for Times Angel Company Overview - **Company Name**: Times Angel - **Established**: 2003, became a publicly listed company in 2021 - **Major Shareholder**: Songbai Orthodontics holds 51.05% of shares, indicating a concentrated ownership structure that supports efficient strategic decision-making [3][12] Industry Insights Domestic Market Performance - **Market Share**: Times Angel holds over 40% of the domestic market share, leading the industry since 2021 [4] - **Revenue Stability**: Despite pressures from local brands, domestic revenue remained stable, with an adjusted profit margin above 19% from 2023 to H1 2025 [4] - **Case Growth**: Domestic case numbers have shown double-digit growth in 2023 and H1 2025, although revenue growth has lagged behind due to price pressures [4] Overseas Business Development - **Growth Driver**: Overseas business has become the main growth engine, with overseas case numbers reaching 52% of total cases in H1 2025, marking a significant increase [2][5] - **Revenue Increase**: Overseas revenue surged to $80.5 million in 2024, with a projected significant profit recovery in 2025 [5] - **Loss Reduction**: Overseas losses narrowed to $5.4 million in H1 2025, indicating a nearing profitability point [2][5] Market Penetration and Growth Potential - **Market Penetration**: The domestic invisible orthodontics market penetration increased from 11% in 2020 to 14% in 2023, with expectations to reach 16% in 2024 and 25% by 2030 [6] - **Growth Drivers**: Key growth drivers include increasing demand from the youth market and expanding needs in lower-tier cities [6] Competitive Landscape - **Market Concentration**: The industry is consolidating, with leading companies like Times Angel and Align Technology capturing over 70% of the market share [6] - **Competitive Pressure**: Smaller manufacturers are exiting the market, creating opportunities for leading firms to capture additional market share [6][10] Global Market Dynamics - **Global Market Size**: The global invisible orthodontics market is projected to be over six times larger than the domestic market by 2024, with significant growth expected [7] - **Regional Distribution**: North America accounts for 39% of the global market, followed by Europe at 32% and Asia-Pacific at 20% [7] Core Competitive Advantages - **Product Range**: Times Angel offers a comprehensive product line catering to diverse market needs, supported by a strong R&D focus [8][9] - **Supply Chain Efficiency**: The company boasts a smart manufacturing system with an average global order delivery time of 8.5 days [9] - **Market Strategy**: Tailored marketing strategies for different regions, focusing on high-quality product promotion in Europe and North America [9] Future Outlook - **Market Share Projections**: Times Angel aims to capture over 20% of the global market share by 2033, with revenue projections reaching $1.6 billion [11][12] - **Revenue Forecast**: Expected revenues for 2025, 2026, and 2027 are $333 million, $412 million, and $495 million, respectively, with growth rates of 25%, 22%, and 20% [12] - **Valuation**: Using a price-to-sales (PS) ratio of 4.8 for 2026, the target market capitalization is estimated at HKD 154.5 billion, translating to a target share price of HKD 90.5 [12] Risks - **Market Expansion Risks**: Potential challenges in overseas market expansion and increased competition [12] - **Legal Risks**: Exposure to patent litigation and geopolitical risks [12]

Core Viewpoint - The company is a leading provider of invisible orthodontic technology and products in China, having surpassed competitors in domestic market share since 2021, with robust performance despite industry pressures. The rapid growth of overseas business has significantly contributed to overall revenue, with overseas cases expected to reach approximately 140,700 in 2024, a year-on-year increase of 326% [3]. Group 1: Domestic Business Growth - The domestic invisible orthodontics market has substantial growth potential, with penetration rates nearing 16% in 2024, compared to 32% in the U.S. in 2020, indicating room for improvement, particularly in the youth/children and grassroots markets [4]. - Market concentration is increasing due to competitive pressures and policy changes, benefiting leading companies like this one as smaller players exit the market [4]. Group 2: International Expansion Potential - The global invisible orthodontics market is significantly larger than the domestic market, with case numbers being eight times higher. The company has opportunities to penetrate markets in the U.S., Europe, Asia-Pacific, and Latin America, where there is considerable room for growth [5]. - The company has established a comprehensive product system and is enhancing its competitive edge through continuous R&D and digital upgrades, leveraging a vast clinical database for complex case handling [5]. - The company’s global market share has increased from 4.5% in 2022 to 10.1% in 2025, with expectations to reach over 20% in the future as it enters a new phase of international expansion [6]. Group 3: Financial Projections - Revenue projections for the company from 2025 to 2027 are estimated at $337 million, $412 million, and $495 million, with net profits of $27 million, $22 million, and $41 million respectively. The company is currently in a growth phase for its overseas business and is valued using a PS method, with a target market value of HKD 15.45 billion and a target share price of HKD 90.5 [6].

Investment Rating - The report gives a "Buy" rating for the company, with a target price of HKD 90.5, compared to the current price of HKD 69.60 [3][8]. Core Insights - The company is a leading provider of invisible orthodontics in China, having surpassed competitors in market share since 2021, and is experiencing robust growth in overseas markets, with a significant increase in case numbers and revenue [1][19]. - The domestic market for invisible orthodontics has substantial growth potential, with penetration rates expected to rise significantly in the coming years, particularly in the youth and grassroots markets [7][52]. - The company has established a strong competitive advantage through product innovation, a robust supply chain, and effective marketing strategies, which have facilitated its expansion into international markets [2][11]. Summary by Sections Section 1: Company Overview - The company has been a key player in the invisible orthodontics sector for over 20 years, achieving the top market position in China since 2021, with over 40% market share [28][19]. - The company has expanded internationally, acquiring a majority stake in a Brazilian orthodontic manufacturer, and has seen overseas case numbers surpass domestic ones by 2025H1 [16][19]. Section 2: Domestic Business Growth Potential - The domestic invisible orthodontics market is under pressure but has significant room for growth, with penetration rates expected to increase from 16% in 2024 to 25% by 2030 [46][52]. - The market is experiencing a consolidation trend, with leading companies benefiting from increased market concentration as smaller players exit due to competitive pressures [56][31]. Section 3: International Expansion Potential - The global market for invisible orthodontics is several times larger than the domestic market, providing substantial growth opportunities for the company [11][19]. - The company has improved its global market share from 4.5% in 2022 to an estimated 10.1% in 2025, with expectations to reach over 20% in the future [2][11]. - Revenue from overseas operations is projected to grow significantly, with estimates of USD 1.6 billion by 2033, driven by increased market penetration and operational efficiencies [11][12]. Section 4: Financial Projections and Valuation - The company is expected to generate total revenues of USD 337 million, USD 412 million, and USD 495 million for the years 2025, 2026, and 2027, respectively, with net profits projected at USD 27 million, USD 22 million, and USD 41 million [3][12]. - The report employs a price-to-sales (P/S) valuation method, estimating a P/S ratio of 4.8X for 2026, leading to a target market capitalization of HKD 154.5 billion [8][12].

Investment Rating - The report assigns a "Buy" rating to the company for the first time [8]. Core Insights - The company is a leading provider of invisible orthodontics in China, having surpassed competitors in domestic market share since 2021, and is experiencing rapid growth in overseas markets [1][28]. - The global invisible orthodontics market presents significant growth opportunities, with the company expected to increase its market share from 10% to over 20% in the coming years [2][11]. - The company’s revenue is projected to grow significantly, with total revenues expected to reach approximately $495 million by 2027, reflecting a compound annual growth rate (CAGR) of 20.4% [3][12]. Summary by Sections Section 1: Company Overview - The company has been a key player in the invisible orthodontics sector for over 20 years, achieving the top market position in China since 2021 [16][28]. - The company has expanded internationally, acquiring a majority stake in a Brazilian orthodontic manufacturer, which has contributed to its overseas case numbers exceeding domestic figures by 2025 [16][19]. Section 2: Domestic Business Growth Potential - The domestic market for invisible orthodontics has substantial growth potential, with penetration rates expected to rise from 16% in 2024 to 25% by 2030 [7][46]. - The market is experiencing consolidation, with leading companies benefiting from increased market concentration as smaller competitors exit due to pricing pressures [10][56]. Section 3: International Expansion Potential - The company’s global market share has increased from 4.5% in 2022 to 10.1% in 2025, with expectations to reach over 20% in the future [2][11]. - The company has established a comprehensive competitive advantage through product innovation, supply chain efficiency, and targeted marketing strategies [2][11]. Section 4: Financial Projections and Valuation - Revenue forecasts for 2025, 2026, and 2027 are $337 million, $412 million, and $495 million respectively, with net profits projected at $27 million, $22 million, and $41 million [3][12]. - The report utilizes a price-to-sales (P/S) valuation method, estimating a target market capitalization of HKD 154.5 billion and a target share price of HKD 90.5 [8][12].

Core Viewpoint - The company, Times Angel, is expected to see a significant increase in net profit for the fiscal year 2025, projecting between $24 million to $30 million, which represents a growth of 140% to 200% compared to the previous fiscal year’s profit of approximately $10 million [2][5]. Group 1: Profit Growth Drivers - The substantial profit increase is attributed to the realization of operational leverage, as the company’s established global sales network and service infrastructure begin to yield benefits [6][10]. - The fixed costs incurred in previous years are now being diluted over a larger business scale, leading to enhanced profit margins [7][8]. - This type of profit growth is more significant than merely increasing sales volume, indicating a transition to a more efficient business model [9][10]. Group 2: Financial Variables - Two additional financial factors were disclosed: delays in the cost progress of some production facilities outside China and the timing of recognizing certain intellectual property-related legal and professional expenses [11][13]. - These factors suggest that the profit growth for 2025 is influenced not only by operational efficiency but also by the timing of expense recognition [14]. Group 3: Industry Implications - For medical device companies, particularly those pursuing globalization, there is often a phase where profit margins significantly improve once the operational framework is established and revenue continues to grow [15][16]. - The performance forecast for Times Angel signals a shift from an "investment phase" to an "efficiency phase," which is crucial for industry executives to understand [17][20]. - The focus should not only be on the current profit figures but also on the structural changes that will affect future profitability [21][22].